<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Autoimmune (including paraneoplastic) encephalitis: Management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Autoimmune (including paraneoplastic) encephalitis: Management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Autoimmune (including paraneoplastic) encephalitis: Management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Hesham Abboud, MD, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Maarten J Titulaer, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Patrick Y Wen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            April F Eichler, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 09, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2713372927">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune encephalitis is a heterogeneous entity that includes paraneoplastic, idiopathic, drug-induced, and postviral causes, often but not always in association with antibodies against either intracellular or cell-surface neuronal antigens. Patients can have severe and wide-ranging manifestations that include mental status changes, psychiatric symptoms, seizures, movement disorders, sleep disruption, dysautonomia, and hypoventilation.
        </p>
        <p>
         The mainstay of treatment is immunomodulatory therapy to stop the immune-mediated attack and ameliorate brain inflammation. Admission to the intensive care unit is needed in a substantial number of patients to manage severe dysautonomia, central hypoventilation, and/or status epilepticus.
        </p>
        <p>
         The initial and long-term management of autoimmune encephalitis, including paraneoplastic encephalitis, will be reviewed here. Clinical features and diagnosis are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
         Other inflammatory disorders of the central nervous system covered in separate topics include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute disseminated encephalomyelitis (ADEM) (see
         <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">
          "Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6208.html" rel="external">
          "Acute disseminated encephalomyelitis (ADEM) in children: Treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14087.html" rel="external">
          "Acute disseminated encephalomyelitis (ADEM) in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (see
         <a class="medical medical_review" href="/z/d/html/131838.html" rel="external">
          "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/132021.html" rel="external">
          "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Treatment and prognosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuromyelitis optica spectrum disorders (NMOSD) (see
         <a class="medical medical_review" href="/z/d/html/14089.html" rel="external">
          "Neuromyelitis optica spectrum disorder (NMOSD): Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/134223.html" rel="external">
          "Neuromyelitis optica spectrum disorder (NMOSD): Treatment and prognosis"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hashimoto encephalopathy/steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT) (see
         <a class="medical medical_review" href="/z/d/html/4821.html" rel="external">
          "Hashimoto encephalopathy"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) (see
         <a class="medical medical_review" href="/z/d/html/1688.html" rel="external">
          "Evaluation and diagnosis of multiple sclerosis in adults", section on 'CLIPPERS'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2471702764">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H3323610424">
         <span class="h2">
          Pathogenic mechanism
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune encephalitis is a heterogeneous entity that includes paraneoplastic, idiopathic, drug-induced, and postviral causes. Pathogenesis is thought to be mediated by one of two mechanisms: antibody-mediated (humoral) effects, largely involving B cells, or cell-mediated effects, largely involving T cells. The distinction is important for selecting appropriate immunomodulatory therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antibody-mediated
         </strong>
         – An antibody-mediated mechanism is suspected in many cases of idiopathic autoimmune encephalitis, especially those associated with antibodies against neuronal cell-surface or synaptic proteins (eg, anti-N-methyl-D-aspartate [NMDA] receptor, anti-leucine-rich glioma inactivated 1 [LGI1] protein). In the three-tier classification system of antibodies associated with autoimmune encephalitis syndromes, all of the intermediate and most of the lower-risk antibodies target cell-surface antigens and are thought to be directly pathogenic via antibody-mediated effects  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          T cell-mediated
         </strong>
         – A T cell-mediated mechanism is likely in cases of classic paraneoplastic encephalitis associated with antibodies against intracellular neuronal proteins (eg, anti-Hu, anti-Ri). Such high-risk onconeuronal antibodies  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 1
         </a>
         ) are not considered to be directly pathogenic. Rather, damage is mediated by cytotoxic T cells and can result in irreversible neuronal degeneration. Most cases of iatrogenic autoimmune encephalitis in the setting of immune checkpoint inhibitors (ICIs) are likely T cell-mediated as well. (See
         <a class="local">
          'Triggers (tumor, infection, drugs)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unknown
         </strong>
         – The pathogenesis of antibody-negative autoimmune encephalitis (no associated cancer or detectable antibody) is unknown, and the relative contribution of antibody- versus T cell-mediated pathology is therefore unclear.
        </p>
        <p>
        </p>
        <p>
         In most cases, initiation of immunomodulatory therapy takes place before the results of the neuronal antibody panel are known. In this setting, clinicians should use indirect clues to a suspected pathogenic mechanism. As an example, antibody-mediated pathology can be presumed in patients with faciobrachial dystonic seizures (suggestive of anti-LGI1 encephalitis) [
         <a href="#rid1">
          1
         </a>
         ] and in patients with a clinical picture typical of anti-NMDA receptor encephalitis  (
         <a class="graphic graphic_table graphicRef111082" href="/z/d/graphic/111082.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. Clinical features of these and other antibody-mediated encephalitides are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Neuronal cell-surface protein antibody syndromes'
         </a>
         .)
        </p>
        <p>
         T cell-mediated pathology can be presumed in patients with known cancer or who have high cancer risk, since most of the classic paraneoplastic syndromes are T cell-mediated. There are exceptions, however, most notably among the intermediate-risk and low-risk antibody syndromes  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 1
         </a>
         ), which are thought to be antibody-mediated whether or not an associated cancer is present (eg, anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid [AMPA] receptor, and anti-gamma-aminobutyric acid B [GABA-B] receptor).
        </p>
        <p class="headingAnchor" id="H2929912425">
         <span class="h2">
          Triggers (tumor, infection, drugs)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potential triggers of autoimmune encephalitis should be treated promptly to hasten neurologic recovery. These include treatment of the associated tumor in paraneoplastic cases, treatment of active infections in parainfectious cases (eg, herpes simplex virus encephalitis) (see
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Association with HSVE'
         </a>
         ), and removal of any potential iatrogenic triggers (eg, ICIs). (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors", section on 'Neurologic'
         </a>
         .)
        </p>
        <p>
         In patients with acute and severe presentations of encephalitis, empiric antimicrobial therapy is appropriate to cover herpes simplex virus (HSV)-1 infection and other major pathogens. Antibiotics and
         <a class="drug drug_general" data-topicid="9335" href="/z/d/drug information/9335.html" rel="external">
          acyclovir
         </a>
         can generally be discontinued if cerebrospinal fluid (CSF) bacterial cultures and HSV polymerase chain reaction (PCR) studies return negative. (See
         <a class="medical medical_review" href="/z/d/html/1284.html" rel="external">
          "Viral encephalitis in adults", section on 'Empiric therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3710896583">
         <span class="h2">
          Severity and care setting
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with autoimmune encephalitis are acutely ill, and initial immunomodulatory therapy is delivered in the inpatient setting. Symptomatic treatment is often needed for symptoms including psychosis, agitation, seizures, involuntary movements, and sleep dysfunction. Patients with severe complications, including dysautonomia, central hypoventilation, and/or status epilepticus, require admission to the intensive care unit. (See
         <a class="local">
          'Supportive care'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H969787294">
         <span class="h1">
          ANTITUMOR THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prompt and adequate treatment of the underlying tumor is fundamental in paraneoplastic neurologic syndromes, as it removes the origin of the aberrant immune response.
        </p>
        <p class="headingAnchor" id="H3949787315">
         <span class="h2">
          Tumor present
         </span>
         <span class="headingEndMark">
          —
         </span>
         In many patients with paraneoplastic encephalitis, neurologic symptoms are resistant to immunomodulatory therapy alone, especially when a classic onconeuronal antibody is present  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. Multidisciplinary care is critical to identify the most appropriate antitumor treatment based on tumor type, stage, and patient characteristics.
        </p>
        <p>
         Improvement or stabilization has been described after tumor treatment in patients with paraneoplastic encephalitis or encephalomyelitis [
         <a href="#rid3">
          3,4
         </a>
         ] as well as those with other paraneoplastic neurologic syndromes, such as opsoclonus-myoclonus-ataxia syndrome [
         <a href="#rid5">
          5
         </a>
         ]. While outcomes are generally poor in paraneoplastic cerebellar degeneration (especially those associated with anti-Yo antibodies) [
         <a href="#rid6">
          6,7
         </a>
         ], individual patients have shown benefit.
        </p>
        <p>
         For patients with metastatic disease, debulking surgery or palliative radiation therapy or chemotherapy may reduce the inappropriate immune drive, resulting in neurologic improvement [
         <a href="#rid8">
          8
         </a>
         ]. Of note, the performance status (eg, Karnofsky Performance Status [KPS]  (
         <a class="graphic graphic_table graphicRef58785" href="/z/d/graphic/58785.html" rel="external">
          table 3
         </a>
         )) is often poor based on the paraneoplastic neurologic symptoms rather than direct effects of the cancer. Low KPS scores in this setting should not be used to postpone or withhold aggressive oncologic management until neurologic symptoms improve. On the contrary, especially in patients with classic onconeuronal antibodies, immunomodulatory therapy without concomitant tumor treatment is rarely effective.
        </p>
        <p>
         For patients with anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, resection of an associated ovarian or testicular teratoma is essential to accelerate remission, in combination with immunomodulatory therapy [
         <a href="#rid9">
          9
         </a>
         ]. Similar principles likely apply to other antibody-mediated syndromes with an associated tumor, although data are limited by their rarity.
        </p>
        <p class="headingAnchor" id="H2629273355">
         <span class="h2">
          Tumor absent on initial screening
         </span>
         <span class="headingEndMark">
          —
         </span>
         Repeat cancer screening is warranted in patients with a paraneoplastic syndrome who do not have a malignancy detected at the time of initial presentation. The extent and frequency of repeat screening are dictated by the clinical phenotype and antibody identified  (
         <a class="graphic graphic_table graphicRef135171" href="/z/d/graphic/135171.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid10">
          10,11
         </a>
         ]. This evaluation is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/5188.html" rel="external">
          "Overview of paraneoplastic syndromes of the nervous system", section on 'Search for occult malignancy'
         </a>
         .)
        </p>
        <p>
         In highly selected scenarios when the suspicion for a paraneoplastic origin is very high and the clinical course is severe but screening investigations are nonspecific or unrevealing, explorative surgery can be considered. The main examples are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Males &lt;50 years of age with Ma2 antibodies – In male patients younger than 50 years of age, there is a very strong association between anti-Ma2 antibodies and testicular tumors, most commonly germ cell tumors. This has led some clinicians to advocate ‘blind’ orchiectomy for suspected microscopic tumor in carefully selected patients with Ma2 antibodies and a paraneoplastic neurologic syndrome in whom no tumor is found after initial screening. In a retrospective study of six such patients with risk factors for a testicular malignancy (new testicular enlargement or risk factors for a germ cell tumor, such as cryptorchidism or microcalcifications on testicular ultrasound) but no overt evidence of cancer on initial screening, pathologic examination showed intratubular germ cell neoplasms in all six [
         <a href="#rid12">
          12
         </a>
         ]. Four of these six patients showed partial neurologic improvement and prolonged stabilization.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Females with anti-NMDA receptor encephalitis – In females of reproductive age, half of anti-NMDA receptor encephalitis cases are associated with an ovarian teratoma [
         <a href="#rid13">
          13
         </a>
         ], which can be microscopic [
         <a href="#rid14">
          14
         </a>
         ]. Therefore, every imaging abnormality should be considered carefully in these patients. For those with negative initial screening who are extremely refractory to immunomodulatory therapy, pelvic/abdominal imaging should be repeated to search for subtle abnormalities that may indicate a small or microscopic teratoma. In such cases with subtle potential abnormalities, exploratory laparotomy may be considered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         By contrast, blind bilateral oophorectomy despite negative pelvic imaging for teratoma is generally
         <strong>
          not
         </strong>
         useful and should only be considered in exceptional patients with extremely severe and refractory clinical picture and after exhausting every effort to identify one affected ovary. This necessitates extensive discussion of the potential benefits and risks, including sterilization, with the family and caregivers [
         <a href="#rid14">
          14
         </a>
         ]. Often, patients who continue to be symptomatic after unilateral oophorectomy and sufficient immunomodulatory therapy simply need longer to recover. Assumption of a microscopic teratoma in the remaining normal ovary is often speculative and may cost a young patient her fertility if an unnecessary resection of a normal ovary is undertaken.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several female patients have been reported with anti-NMDA receptor encephalitis and immunomodulatory therapy-refractory disease who have had good outcomes after empiric oophorectomy despite pelvic imaging that was considered negative [
         <a href="#rid14">
          14
         </a>
         ]. However, natural history and late response to immunomodulatory therapies could have confounded the apparent response after oophorectomy. Nevertheless, microscopic teratomas were identified in at least some of these patients, which suggested a direct paraneoplastic association.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H516436976">
         <span class="h1">
          INITIAL IMMUNOMODULATORY THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H48195854">
         <span class="h2">
          Timing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunomodulatory therapy should be started as soon as possible. Delayed treatment is one of the factors most consistently associated with poor outcomes after autoimmune encephalitis [
         <a href="#rid15">
          15,16
         </a>
         ].
        </p>
        <p>
         It is unnecessary and potentially harmful to wait for results of the neuronal antibody panel before starting treatment. In patients meeting criteria for definite autoimmune limbic encephalitis  (
         <a class="graphic graphic_table graphicRef111085" href="/z/d/graphic/111085.html" rel="external">
          table 5
         </a>
         ), probable anti-N-methyl-D-aspartate(NMDA) receptor encephalitis  (
         <a class="graphic graphic_table graphicRef111082" href="/z/d/graphic/111082.html" rel="external">
          table 2
         </a>
         ), or probable anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis, immunomodulatory therapy can be started once infectious causes have been ruled out based on preliminary cerebrospinal fluid (CSF) results  (
         <a class="graphic graphic_table graphicRef111083" href="/z/d/graphic/111083.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis", section on 'Diagnostic approach'
         </a>
         .)
        </p>
        <p>
         In patients not meeting these criteria, a thorough evaluation for alternative causes or consultation with a neuroimmunologist is advisable before starting empiric immunomodulatory therapy.
        </p>
        <p class="headingAnchor" id="H2868015308">
         <span class="h2">
          Goals and response assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goal of acute immunomodulatory therapy is to achieve maximal clinical response by suppressing the pathogenic immune response. Response should be assessed clinically by history and neurologic examination at regular intervals based on clinical acuity (eg, daily during initial immunomodulatory therapy, weekly if
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         is being administered, every one to three months during a taper). Patients with baseline neuroimaging abnormalities should have repeat imaging within the first three months, although radiologic improvement may lag behind clinical recovery. Electroencephalography (EEG) improvement may also indicate a favorable response to immunomodulatory therapy.
        </p>
        <p>
         An adequate clinical response to first-line immunomodulatory therapy is not formally defined and varies based not only on the symptom complex but also on the antibody syndrome. Some symptoms take longer than others to improve. Examples of an adequate clinical response may include improvement in mental state, cessation of status epilepticus or decreased frequency of seizures, achievement of autonomic stability, resolution of dangerous hyperkinetic movements, or resolution of agitation and psychosis.
        </p>
        <p>
         Serial antibody testing is not generally helpful in assessing response. While some laboratories may provide quantification of antibody levels, antibody burden has not been validated as an indicator of treatment response. It may be reasonable to repeat antibody levels when a patient has reached clinical remission so that a baseline is available for comparison if the patient relapses or otherwise worsens clinically. Antibodies may also be useful to help interpret the significance of ongoing symptoms after initial therapy. (See
         <a class="local">
          'Patients with refractory disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1161974285">
         <span class="h2">
          Selection of initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based on clinical experience, case series, and indirect evidence from other autoimmune disorders, high-dose glucocorticoids, intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG), and therapeutic plasma exchange (TPE) are all considered first-line immunomodulatory therapies for confirmed or suspected autoimmune encephalitis, and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         and
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         are the most common second-line therapies [
         <a href="#rid18">
          18
         </a>
         ]. Absent randomized trials, selection of a specific regimen is based on mechanism of disease and clinical severity  (
         <a class="graphic graphic_algorithm graphicRef142786" href="/z/d/graphic/142786.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3006773424">
         <span class="h3">
          Antibody-mediated mechanism
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all patients with a known or suspected antibody-mediated mechanism of autoimmune encephalitis  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 1
         </a>
         ), we suggest initial treatment with high-dose glucocorticoids. In addition, we suggest concurrent use of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         or TPE in patients with any of the following risk factors for worse outcomes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe disease (eg, respiratory failure, severe dysautonomia, refractory status epilepticus)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Definite or probable anti-NMDA receptor encephalitis  (
         <a class="graphic graphic_table graphicRef111082" href="/z/d/graphic/111082.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         The choice between
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         and TPE in combination with steroids is individualized and may vary by center. IVIG is often favored because it is more readily available and does not require a central line. TPE is an alternative to IVIG when there are relative contraindications to IVIG, such as high thromboembolic risk or severe hyponatremia. Administration and outcomes are reviewed below. (See
         <a class="local">
          'Glucocorticoids'
         </a>
         below and
         <a class="local">
          'Intravenous immune globulin'
         </a>
         below and
         <a class="local">
          'Therapeutic plasma exchange'
         </a>
         below.)
        </p>
        <p>
         For patients selected for glucocorticoids alone who do not improve by 14 days from the start of the steroid course or do not tolerate high-dose steroids, we start
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         or TPE. For those who have received concurrent high-dose steroids and IVIG/TPE initially and do not respond adequately by 14 days, we suggest starting a second-line therapy (eg,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ) rather than administering a second round of the first-line therapy [
         <a href="#rid18">
          18
         </a>
         ]. A minority of experts (15 percent) favor use of rituximab initially in combination with steroids and/or IVIG/TPE, rather than stepwise escalation [
         <a href="#rid18">
          18
         </a>
         ]. Before each escalation step, it is important to review the diagnosis and reconsider alternative diagnoses.
        </p>
        <p>
         If there is no improvement following
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (eg, four weeks after first dose), we begin
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . In severe cases, cyclophosphamide may be started at the same time as rituximab. In children,
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         may be an alternative third-line agent; in adults, we prefer cyclophosphamide because it has more evidence to support its use than tocilizumab and other investigational therapies. (See
         <a class="local">
          'Cyclophosphamide'
         </a>
         below and
         <a class="local">
          'Patients with refractory disease'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1184401669">
         <span class="h3">
          T cell-mediated mechanism
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients with a known or suspected T cell-mediated mechanism, including those with immune checkpoint inhibitor (ICI)-associated encephalitis, we suggest high-dose glucocorticoids alone as first-line therapy. We do not use
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         or TPE initially in most of these patients, as long as a T cell-mediated mechanism is likely based on clinical clues. However, some experts favor combination therapy in all patients with severe presentations for whom a mechanism has not yet been confirmed by antibody testing results, in order to address both antibody-mediated and T cell-mediated mechanisms [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="local">
          'Pathogenic mechanism'
         </a>
         above.)
        </p>
        <p>
         For patients with a poor response to high-dose glucocorticoids, the likelihood of T cell- versus antibody-mediated pathology should be reassessed based on additional testing results. If a classic onconeuronal antibody syndrome has been confirmed, our preferred second-line therapy is
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         (see
         <a class="local">
          'Cyclophosphamide'
         </a>
         below). For severely affected patients whose antibody results remain pending, a course of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         or TPE is reasonable before considering cyclophosphamide. If an antibody against a cell-surface antigen such as gamma-aminobutyric acid B (GABA-B) receptor or alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor has been identified, preferred therapies for escalation are IVIG, TPE, and/or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         . (See
         <a class="local">
          'Antibody-mediated mechanism'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1476338466">
         <span class="h3">
          Checkpoint inhibitor-associated
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the subset of patients with ICI-associated autoimmune encephalitis, cancer immunotherapy  (
         <a class="graphic graphic_table graphicRef130841" href="/z/d/graphic/130841.html" rel="external">
          table 7
         </a>
         ) should be stopped. Most patients respond well to high-dose glucocorticoids [
         <a href="#rid19">
          19,20
         </a>
         ]. For those with an inadequate response to steroids, or for those with a particularly severe syndrome at presentation,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         or TPE is reasonable to add  (
         <a class="graphic graphic_table graphicRef116846" href="/z/d/graphic/116846.html" rel="external">
          table 8
         </a>
         ), even if an antibody-mediated mechanism has not been confirmed.
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         may be considered in refractory cases or when a neuronal antibody has been detected.
        </p>
        <p>
         Encephalitis is usually considered to be a moderate to severe (grade 3 or 4) immune-related adverse event, which warrants permanent discontinuation of ICI therapy [
         <a href="#rid21">
          21,22
         </a>
         ]. Rechallenge with an ICI may be carefully considered in selected cases but would require extensive counseling and consideration of risks and benefits of tumor progression versus recurrence of neurologic symptoms. (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors", section on 'Retreatment after prior toxicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2393994684">
         <span class="h3">
          Antibody-negative (unknown)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with antibody-negative autoimmune encephalitis (ie, no neuronal antibody detected and no cancer), we use the same approach as outlined above for antibody-mediated encephalitis (see
         <a class="local">
          'Antibody-mediated mechanism'
         </a>
         above). If there is no response to stepwise therapy including
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , or if a cancer is diagnosed subsequently, we consider
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         .
        </p>
        <p>
         In regions where neuronal antibody testing is not available but autoimmune encephalitis is highly suspected, first-line agents can be used, but only after a thorough exclusion of alternative diagnoses. It should be noted that the likelihood of autoimmune encephalitis in such regions is unknown and is probably different from the likelihood reported in the published literature from centers with access to testing [
         <a href="#rid23">
          23
         </a>
         ]. If the patient is refractory to first-line therapy, we advise consultation with reference laboratories and neuroimmunology experts before starting second-line therapy.
        </p>
        <p class="headingAnchor" id="H1011494665">
         <span class="h2">
          Administration of specific therapies
         </span>
        </p>
        <p class="headingAnchor" id="H2480489929">
         <span class="h3">
          Glucocorticoids
         </span>
         <span class="headingEndMark">
          —
         </span>
         A typical high-dose steroid regimen used for known or suspected autoimmune encephalitis in adults is intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (IVMP) 1000 mg daily for 3 to 7 days [
         <a href="#rid16">
          16-18
         </a>
         ]. The recommended weight-based dose of IVMP for children is 20 to 30 mg/kg/day (maximum 1000 mg per day) for 3 to 5 days [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         We prefer pulsed IVMP over daily oral glucocorticoids for acute therapy because it allows for a clearer determination of clinical response and helps to avoid the side effects and interactions of long-term daily steroids in patients who are not deriving benefit. Shorter courses (eg, 1000 mg daily for 1 to 3 days) are often used for subsequent pulses in the setting of an extended taper. There are no data to inform superiority of one dosing schedule or formulation over another.
        </p>
        <p>
         Clinicians should be aware that steroid psychosis may mask treatment response in encephalitis patients with psychiatric presentations. We do not consider psychosis to be a contraindication to use of high-dose glucocorticoids with appropriate monitoring and supportive care; in some cases, psychosis improves dramatically with steroids. Uncontrolled diabetes or hypertension are relative contraindications to use. Additional side effects and safety monitoring are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
         High-dose glucocorticoids have long been used to treat suspected autoimmune encephalitis based on their broad and rapid immunosuppressive effects. In a survey of 68 members of the Autoimmune Encephalitis Alliance Clinicians Network, glucocorticoid therapy alone or combined with other first-line agents was the most frequently selected option (selected by 84 percent of network members) for initial treatment of patients with an unspecified autoimmune encephalitis presentation [
         <a href="#rid18">
          18
         </a>
         ]. Glucocorticoid therapy was also the most frequently selected option for patients with anti-NMDA receptor, anti-LGI1, and paraneoplastic encephalitis presentations.
        </p>
        <p>
         Some subtypes of autoimmune encephalitis tend to be highly responsive to glucocorticoids as monotherapy. These include anti-LGI1 encephalitis [
         <a href="#rid24">
          24
         </a>
         ], anti-glial fibrillary acidic protein (GFAP) encephalomyelitis [
         <a href="#rid25">
          25
         </a>
         ], and ICI-associated encephalitis [
         <a href="#rid21">
          21,26
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2785604692">
         <span class="h3">
          Intravenous immune globulin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dosing of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         for autoimmune encephalitis is not standardized. A common approach is to administer a dose of 2 g/kg divided over two to five days [
         <a href="#rid13">
          13,18
         </a>
         ]. The dose is the same whether IVIG is being used in combination with high-dose glucocorticoids for severe presentations or, uncommonly, as initial monotherapy in patients with a contraindication to glucocorticoids (for example, anti-glutamic acid decarboxylase [GAD65] encephalitis with concomitant poorly controlled type 1 diabetes mellitus [
         <a href="#rid27">
          27
         </a>
         ]).
        </p>
        <p>
         The increased risk of thromboembolism might complicate the use of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         in patients with paraneoplastic encephalitis, in whom the thromboembolic risk is already increased because of underlying cancer. Aggressive mechanical and chemical prophylaxis against deep vein thrombosis can reduce this risk when the use of IVIG is necessary in such patients. New or worsening hyponatremia is a potential concern with IVIG, especially in patients with anti-LGI1 encephalitis who may present with hyponatremia [
         <a href="#rid1">
          1
         </a>
         ]. However, this complication is rare in our experience. Administration and toxicities of IVIG are reviewed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">
          "Intravenous immune globulin: Adverse effects"
         </a>
         .)
        </p>
        <p>
         Most of the evidence supporting use of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         comes from studies in patients with autoimmune encephalitis due to specific antibodies such as anti-NMDA receptor or anti-LGI1, and the timing of administration varies. Data on IVIG as monotherapy include results of a small randomized placebo-controlled trial of IVIG in 17 patients with anti-LGI1 or anti-contactin-associated protein-like 2 (CASPR2) encephalitis and seizures who enrolled within a year of symptom onset [
         <a href="#rid28">
          28
         </a>
         ]. At five-week follow-up, the IVIG group was more likely to experience a ≥50 percent reduction in seizure frequency over baseline (75 versus 22 percent) [
         <a href="#rid28">
          28
         </a>
         ]. By contrast, in a retrospective study of 118 patients with anti-LGI1 encephalitis, analysis of the 70 patients who received initial monotherapy with glucocorticoids (n = 49) or IVIG (n = 21) suggested that glucocorticoid monotherapy might be more effective than IVIG in this patient group in the acute phase [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Evidence on the role of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         in combination with glucocorticoids is largely retrospective [
         <a href="#rid13">
          13
         </a>
         ]. A 2021 meta-analysis collected patient-level data on 1550 patients with anti-NMDA receptor encephalitis that were reported in the literature across 652 mostly retrospective studies [
         <a href="#rid16">
          16
         </a>
         ]. In a multivariable analysis of 582 patients with functional outcome data available (poor outcome defined as a score of ≥3 on the modified Rankin scale), initial treatment factors associated with improved functional outcome at 12 months included use of glucocorticoids plus IVIG (odds ratio [OR] 0.37, 95% CI 0.15-0.91) and use of all three first-line agents together (OR 0.36, 95% CI 0.13-0.97).
        </p>
        <p class="headingAnchor" id="H1217777821">
         <span class="h3">
          Therapeutic plasma exchange
         </span>
         <span class="headingEndMark">
          —
         </span>
         TPE can provide rapid removal of pathologic antibodies in the acute setting. A common regimen consists of 5 to 10 every-other-day sessions. In centers with established pathways for use, plasma exchange is a reasonable alternative to
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         in combination with high-dose glucocorticoids or as an alternative to high-dose glucocorticoids in patients with contraindications.
        </p>
        <p>
         The main safety considerations relate to increased risk of bleeding and line-related complications, including thromboembolism and infection. Plasma exchange can also have a negative effect on blood pressure, which can be problematic in dysautonomic patients. It is also less suitable for agitated patients, children, or those with poorly controlled hyperkinetic movement disorders. (See
         <a class="medical medical_review" href="/z/d/html/7942.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Complications"
         </a>
         .)
        </p>
        <p>
         Retrospective studies in anti-NMDA receptor and mixed-cause autoimmune encephalitis suggest that TPE combined with glucocorticoids is superior to glucocorticoid monotherapy [
         <a href="#rid29">
          29,30
         </a>
         ]. A 2021 meta-analysis of therapeutic regimens in anti-NMDA receptor encephalitis also found that TPE alone or combined with glucocorticoids and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         was associated with better functional outcome at one year after presentation [
         <a href="#rid16">
          16
         </a>
         ]. Anti-NMDA receptor encephalitis is considered a category I disorder based on low-quality evidence by the American Society for Apheresis, indicating that TPE is accepted as a first-line therapy alone or in conjunction with other therapeutic modalities [
         <a href="#rid31">
          31
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1659422309">
         <span class="h3">
          Rituximab
         </span>
         <span class="headingEndMark">
          —
         </span>
         Common
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         dosing regimens for autoimmune encephalitis include 375 mg/m
         <sup>
          2
         </sup>
         weekly for four weeks or two doses of 1000 mg given two weeks apart. Rituximab is preferred over
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         as escalation therapy in children given its relative safety [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         In studies of anti-NMDA receptor and mixed-type autoimmune encephalitis, the use of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         was associated with better functional outcomes in patients refractory to first-line agents [
         <a href="#rid13">
          13,33
         </a>
         ]. This positive effect seems most pronounced in anti-NMDA receptor and anti-CASPR2 serotypes and is less robust in anti-LGI1 and anti-GAD65 serotypes [
         <a href="#rid33">
          33
         </a>
         ]. The use of rituximab as a rescue therapy in the acute setting has also been associated with decreased relapse rates in patients with anti-NMDA receptor encephalitis [
         <a href="#rid13">
          13,16,33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1553958683">
         <span class="h3">
          Cyclophosphamide
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          Cyclophosphamide
         </a>
         is anecdotally preferred in patients with presumed T cell-mediated pathology, including patients with confirmed or highly suspected paraneoplastic encephalitis (high-risk paraneoplastic antibody against intracellular antigens and/or cancer consistent with the clinical phenotype  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 1
         </a>
         )) [
         <a href="#rid10">
          10
         </a>
         ]. It is also used as a second- or third-line therapy in patients with known or presumed antibody-mediated pathology who do not respond adequately to first-line immunomodulatory therapy. (See
         <a class="local">
          'T cell-mediated mechanism'
         </a>
         above and
         <a class="local">
          'Antibody-mediated mechanism'
         </a>
         above.)
        </p>
        <p>
         Dosing is mostly derived from studies in lupus cerebritis [
         <a href="#rid34">
          34
         </a>
         ]. The usual dose is 600 to 750 mg/m
         <sup>
          2
         </sup>
         monthly for an average of six months. Another dosing regimen based on studies from antineutrophil cytoplasmic antibody (ANCA)-related vasculitis includes three induction courses of 15 mg/kg (minus potential dose reduction for age, leucocyte count, and kidney function) every 14 days followed by consolidation with 500 mg every two weeks or 1000 mg every four weeks for two to six months depending on recovery [
         <a href="#rid35">
          35
         </a>
         ]. Since
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         toxicity is related to its cumulative dose [
         <a href="#rid36">
          36
         </a>
         ], clinicians should avoid high or extended doses of cyclophosphamide. For patients who show significant clinical improvement and have also received
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , only a few courses of cyclophosphamide may be needed, thus limiting toxicity.
        </p>
        <p>
         Supporting evidence for
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         consists mainly of clinical experience, expert opinion, and observational studies. In a prospective cohort study of over 500 patients with anti-NMDA receptor encephalitis, treatment responses were similar for cyclophosphamide,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , or the combination [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3693399330">
         <span class="h1">
          SUBSEQUENT IMMUNOMODULATORY THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H3384820184">
         <span class="h2">
          Patients with clinical response
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rapid interruption of immune suppression can result in early recurrence of autoimmune encephalitis, possibly due to incomplete clearance of the pathologic antibody [
         <a href="#rid13">
          13,16
         </a>
         ]. Therefore, we suggest use of a tapering strategy once patients have achieved maximal clinical response to initial immunomodulatory therapy.
        </p>
        <p>
         The most common tapering strategies are an oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         taper, monthly intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (IVMP), monthly intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG), and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         . Duration is individualized but typically extends over a two- to six-month period [
         <a href="#rid18">
          18
         </a>
         ]. Choice of a specific strategy is largely determined by the first-line therapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients treated with IVMP alone
         </strong>
         – For patients who achieve clinical remission with IVMP alone, a transition to an oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         taper is reasonable, starting with 0.5 to 1 mg/kg and tapering slowly over three to six months. An alternative is to repeat IVMP pulses at four-week intervals for two to six months, or with gradually spaced-out infusions over up to six months. Nonsteroid strategies (eg,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         ,
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ) are also an option for patients with poor tolerance for glucocorticoids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients treated with IVMP plus
         </strong>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         <strong>
          or therapeutic plasma exchange (TPE)
         </strong>
         – For patients who achieve clinical remission after multiple first-line agents, any of the initial agents can be selected as a tapering strategy. Monthly IVIG for up to six months (or more in patients with a history of relapse) is a strategy that avoids additional glucocorticoid exposure and toxicities, although prolonged courses of IVIG also carry risks and burdens, and the amount of data for steroids are much more extensive than for IVIG in this setting. In a meta-analysis of over 500 patients with anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, monthly IVIG for six months or more was also associated with decreased risk of relapse, although the number of patients treated in this manner was small [
         <a href="#rid16">
          16
         </a>
         ]. A single course of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         is yet another option.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients treated with
         </strong>
         <strong>
          rituximab
         </strong>
         – Patients who receive
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         as a second-line therapy are expected to have B cell depletion for nearly six months or longer. In this sense, rituximab acts as both a second-line therapy and a tapering strategy. In patients with anti-NMDA receptor encephalitis, large observational studies have found that patients who received rituximab as a second-line agent were less likely to relapse than those who did not receive rituximab [
         <a href="#rid13">
          13,16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients treated with
         </strong>
         <strong>
          cyclophosphamide
         </strong>
         – Similar to
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         achieves more prolonged immune suppression than the first-line therapies, and a bridging strategy beyond the planned initial course of cyclophosphamide may not be needed for patients who have achieved clinical remission unless they have relapsed with prior attempts to discontinue therapy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1654716698">
         <span class="h2">
          Patients with refractory disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         A wide range of alternative immunomodulatory agents are being explored in patients with refractory autoimmune encephalitis who have not responded to standard therapies including
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         and/or
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . Among these, the interleukin-6 (IL-6) inhibitor
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         has received the most attention. Participation in clinical trials is encouraged.
        </p>
        <p>
         Of note, in patients with considerable deficits who reach a plateau, repeat antibody levels may be considered. High residual antibodies in cerebrospinal fluid (CSF) have been associated with poorer outcomes in anti-NMDA receptor encephalitis [
         <a href="#rid37">
          37
         </a>
         ], suggesting a rationale for repeating or escalating immunomodulatory therapy, whereas absent antibodies would not support escalation in this context.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Interleukin-6 (IL-6) inhibitors
         </strong>
         – IL-6 is implicated in the maturation of B cells into plasmablasts and plasma cells. It also acts as a proinflammatory cytokine and inhibits T-regulatory cells.
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          Tocilizumab
         </a>
         ,
         <a class="drug drug_general" data-topicid="129293" href="/z/d/drug information/129293.html" rel="external">
          satralizumab
         </a>
         , and other IL-6 inhibitors could therefore be useful in the treatment of autoimmune encephalitis with antibody-mediated or T cell-mediated mechanisms.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         International consensus recommendations for pediatric anti-NMDA receptor encephalitis include
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         as an option for rituximab-refractory patients, based on its overall safety profile compared with
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         [
         <a href="#rid32">
          32
         </a>
         ]. Increased infection risk and neutropenia are complications of special concern, however, since IL-6 inhibition may prevent the febrile reaction and mask signs of infection. Additional safety considerations are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/129345.html" rel="external">
          "Interleukin 6 inhibitors: Biology, principles of use, and adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Supporting data include a retrospective study of 91 patients with mixed-type autoimmune encephalitis refractory to
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , in which 30 patients who received
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         had improved functional outcome scores at two months compared with those treated with additional rituximab or observation [
         <a href="#rid38">
          38
         </a>
         ]. Another study showed that a treatment regimen consisting of teratoma removal, glucocorticoids,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , rituximab, and tocilizumab (T-SIRT) in anti-NMDA receptor encephalitis might add some benefit to all other treatment combinations not including tocilizumab [
         <a href="#rid39">
          39
         </a>
         ]. The T-SIRT regimen was most beneficial when completed within one month from symptom onset. However, a major limitation of both studies is that treatments were administered sequentially, and the potential benefit of tocilizumab was strongly confounded by delayed effects of earlier therapies, especially rituximab.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="129293" href="/z/d/drug information/129293.html" rel="external">
          Satralizumab
         </a>
         is a longer-acting IL-6 inhibitor that has regulatory approval in the United States (US) for treatment of neuromyelitis optica spectrum disorder (NMOSD). Based on its utility in NMOSD [
         <a href="#rid40">
          40,41
         </a>
         ], satralizumab is being studied in an ongoing clinical trial in patients with anti-NMDA receptor or anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT05503264%3Fterm%3Dsatralizumab%26cond%3DNMDA-R%2BEncephalitis%26draw%3D2%26rank%3D1&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPOduzkyDP4dQypZtSO74oZpStBQOeXc32VwFzLDkiuraL4ze7qge2GZ5sQvEYNwYPHV3x02kJTq2Eo1nUdL9o9NPHIwnJ2U1JlHjf4Pl%2BSkOQ%3D%3D&amp;TOPIC_ID=140809" target="_blank">
          NCT05503264
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          B cell-depleting therapies
         </strong>
         – B cell-depleting therapies other than
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         are also under investigation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="128443" href="/z/d/drug information/128443.html" rel="external">
          Inebilizumab
         </a>
         is an anti-CD19 monoclonal antibody that depletes B cells as well as antibody-producing CD19-positive plasmablasts [
         <a href="#rid42">
          42
         </a>
         ], which could offer an advantage over
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         and other anti-CD20 agents. Inebilizumab has shown efficacy against early relapses in NMOSD and has regulatory approval in the US for aquaporin-4 (AQP4) antibody-positive disease [
         <a href="#rid43">
          43
         </a>
         ]. A trial of inebilizumab in patients with anti-NMDA receptor encephalitis is in progress (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04372615%3Fterm%3Dinebilizumab%26cond%3DAnti-NMDA%2BReceptor%2BEncephalitis%26draw%3D2%26rank%3D1&amp;token=4NF5Ptic01G9G6iBZib%2BHpXFJP%2BSLj7HhjG%2FPsObpX9MNaVeMXDT9UKj8M3CJTQNgBWGFd1WUKoTE%2BIEhfrwNtGHjcwb%2B47mgZ7vyntWZkXqxRhKXqAKwCTpoWbWMsreVRdy%2FGCWZ0m34S84lM6tmgga%2ByGxCjDRkCAyA155zwo%3D&amp;TOPIC_ID=140809" target="_blank">
          NCT04372615
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A single-center clinical trial of
         <a class="drug drug_general" data-topicid="112485" href="/z/d/drug information/112485.html" rel="external">
          ocrelizumab
         </a>
         , a humanized anti-CD20 monoclonal antibody, as a second-line therapy for autoimmune encephalitis was aborted due to low recruitment [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bortezomib
         </strong>
         – The proteasome inhibitor
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         inhibits differentiation and survival of immune cells, especially plasma cells [
         <a href="#rid45">
          45
         </a>
         ]. It is approved for treatment of multiple myeloma. A small retrospective study showed improvement in four out of five patients with anti-NMDA receptor encephalitis who failed to respond to conventional first- and second-line therapies [
         <a href="#rid46">
          46
         </a>
         ]. A meta-analysis of 29 published cases concluded that bortezomib was associated with a favorable outcome in 55 percent of patients with refractory anti-NMDA receptor encephalitis [
         <a href="#rid47">
          47
         </a>
         ]. Based on this preliminary data, a clinical trial of bortezomib in autoimmune encephalitis is recruiting (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT03993262%3Fterm%3Dbortezomib%26cond%3DAutoimmune%2BEncephalitis%26draw%3D2%26rank%3D1&amp;token=XqYfEpIx0o0WaLyeX%2BweUYDNSiv3tyWhome0WQKwUcWaqfCFn0%2FpCtbrdPXZeGonWvA36IEyHDSlInmn8htJp52KQGm%2FnMusikg8miGRNPi%2FR%2FP768qoixHZ%2B38xumTFQeeBKmvYGlqTStAnKh%2FDRQ%3D%3D&amp;TOPIC_ID=140809" target="_blank">
          NCT03993262
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neonatal Fc receptor antagonists
         </strong>
         – A trial of
         <a class="drug drug_general" data-topicid="141867" href="/z/d/drug information/141867.html" rel="external">
          rozanolixizumab
         </a>
         , a monoclonal antibody against the neonatal Fc receptor, is in progress in patients with anti-LGI1 encephalitis (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT04875975%3Fterm%3Drozanolixizumab%26draw%3D2%26rank%3D6&amp;token=nbsXe3i4qfUea5RCPRHtOS7yhoEzH%2BMCpwZ1%2F1ekxPNivkQzuYfW4OqkW%2BLjDqMSXIZxdoU2Jvpfk%2B95Cvvp4k31CW38%2FKnyI0875FWUSnPE%2B40tATdjbF3II2Mq4Kj7&amp;TOPIC_ID=140809" target="_blank">
          NCT04875975
         </a>
         ). The rationale is based on the efficacy of the human
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         G 1 (IgG1) Fc-fragment efgartigimod in myasthenia gravis [
         <a href="#rid48">
          48
         </a>
         ]. Both agents share a similar mechanism of action targeting the neonatal Fc receptor, which leads to increased degradation of IgG including pathologic antibodies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Others
         </strong>
         – Other agents for which more data are needed before clinical use in autoimmune encephalitis include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Low-dose interleukin-2 (IL-2) – In a small retrospective case series without a comparator group, low-dose IL-2 was associated with clinical improvement in 6 out of 10 patients with autoimmune encephalitis refractory to second-line therapy [
         <a href="#rid49">
          49
         </a>
         ]. Neutropenia was seen in one patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tofacitinib – In an uncontrolled retrospective case series of patients with refractory autoimmune encephalitis, the Janus kinase inhibitor
         <a class="drug drug_general" data-topicid="87040" href="/z/d/drug information/87040.html" rel="external">
          tofacitinib
         </a>
         was associated with a good response in two out of eight patients, partial response in three, and no response in three [
         <a href="#rid50">
          50
         </a>
         ]. Both patients with good response had anti-myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), a demyelinating inflammatory central nervous system disease with different target and pathogenic mechanism than prototypical autoimmune encephalitides. (See
         <a class="medical medical_review" href="/z/d/html/132021.html" rel="external">
          "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anakinra – A few case reports describe clinical improvement with the interleukin-1 (IL-1) receptor blocker
         <a class="drug drug_general" data-topicid="9246" href="/z/d/drug information/9246.html" rel="external">
          anakinra
         </a>
         in patients with treatment-refractory central nervous system inflammatory disorders [
         <a href="#rid51">
          51,52
         </a>
         ]. Responsive cases were mostly demyelinating in nature (acute disseminated encephalomyelitis [ADEM], primary progressive multiple sclerosis) and had pathologic confirmation of microglial predominant infiltrates. Several cases of seronegative autoimmune encephalitis/meningoencephalitis did not show a response [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Daratumumab – A few case reports suggest that the anti-CD38 monoclonal antibody
         <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">
          daratumumab
         </a>
         may be of value in treatment-refractory autoimmune encephalitis [
         <a href="#rid53">
          53,54
         </a>
         ]. CD38 is present on the surface of plasma cells, natural killer cells, and some T cell populations.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H95986432">
         <span class="h2">
          Relapsed disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune encephalitis can follow a monophasic or relapsing course. In general, the risk of relapse is highest in patients with clinically relevant neuronal cell-surface antibodies (eg, anti-LGI1, anti-contactin-associated protein-like 2 [CASPR2]) and lowest in postviral (eg, anti-NMDA receptor encephalitis occurring after herpes simplex virus 1 [HSV1] encephalitis) and iatrogenic (eg, immune checkpoint inhibitor [ICI]-associated) cases [
         <a href="#rid17">
          17,55,56
         </a>
         ]. Most relapses occur at relatively short intervals from the index illness while immunomodulatory therapies are being tapered.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk of relapse
         </strong>
         – Accurate estimates of relapse risk are difficult due to multiple factors, including the rarity of individual subtypes; earlier use of therapies such as
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , which may lower the risk of relapse; and challenges in defining true relapse. In retrospective cohort studies, recurrence rates in autoimmune encephalitis associated with neuronal cell-surface antibodies range from approximately 10 to 40 percent [
         <a href="#rid13">
          13,57-60
         </a>
         ]. In some subtypes, such as anti-LGI1 encephalitis, relapses tend to be phenotypically identical to the initial episode [
         <a href="#rid61">
          61,62
         </a>
         ], while in others, like anti-NMDA receptor encephalitis, relapses are generally similar but milder in severity [
         <a href="#rid13">
          13
         </a>
         ]. Most relapses in anti-CASPR2 encephalitis are a milder form of the initial presentation, with exceptions [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – Patients with a suspected relapse should be examined carefully for secondary causes of worsening. Fluctuations in cognition, symptomatic seizures, and transient worsening of residual sequelae are common during recovery and may not indicate recurrent encephalitis. The likelihood of a relapse should be considered in the context of the encephalitis subtype, clinical symptoms, and supporting evidence including magnetic resonance imaging (MRI), EEG, and/or CSF studies. Patients should also be evaluated for occult or recurrent neoplasm when appropriate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Confirmed relapses should be treated initially with glucocorticoids,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , and/or TPE, with a goal of rapidly reinducing clinical remission. Selection is individualized based on treatment history, pathogenic mechanism, and clinical severity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, most patients require initiation of longer-term immunosuppression to prevent further relapses.
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          Azathioprine
         </a>
         and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         mofetil have traditionally been used in this setting, overlapping with oral glucocorticoids for at least three to six months. Maintenance
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         has also been used. However, increasing evidence and expert consensus support use of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         as an alternative in patients with anti-NMDA receptor encephalitis as well as other subtypes [
         <a href="#rid64">
          64
         </a>
         ]. Supporting data in patients with anti-NMDA receptor encephalitis suggest that rituximab has a long-term immunosuppressive effect that lowers relapse risk when used as upfront therapy as well as in those with subsequent relapses [
         <a href="#rid13">
          13,16,60
         </a>
         ]. Mycophenolate or azathioprine may still be preferred in subtypes in which there is stronger evidence for T cell-mediated immunity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         takes effect more quickly than either
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         and might be less carcinogenic than other agents [
         <a href="#rid59">
          59,65
         </a>
         ]. It is generally not necessary to give repeated or maintenance doses of rituximab after an initial course in patients with autoimmune encephalitis. Further considerations on dosing and monitoring of rituximab for chronic immunomodulatory therapy are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/7501.html" rel="external">
          "Rituximab: Principles of use and adverse effects in rheumatoid arthritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The optimal duration of maintenance therapy in patients with relapsed disease is unknown and should be individualized. Factors to consider include the antibody type, type and severity of prior attacks, reversibility of symptoms, tolerability of the immunosuppressive therapy, and patient comorbidities and cancer risk. Expert opinion supports an initial treatment period of three years, followed by re-evaluation and attempt to withdraw maintenance immunosuppression [
         <a href="#rid55">
          55,59,61,64,65
         </a>
         ]. Patients who have more than one relapse while on immunosuppression or while being weaned should be considered for extended or escalated immunosuppression [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2838948356">
         <span class="h1">
          SUPPORTIVE CARE
         </span>
        </p>
        <p class="headingAnchor" id="H592356083">
         <span class="h2">
          Intensive care management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with severe autoimmune encephalitis often require high doses of sedation, antiseizure medications, and other symptomatic therapies during the acute phase of illness [
         <a href="#rid66">
          66
         </a>
         ]. Specific complications include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Status epilepticus
         </strong>
         – Status epilepticus should be treated with a standard protocol, including a fast-acting intravenous benzodiazepine followed by intravenous loading of appropriate antiseizure medications  (
         <a class="graphic graphic_algorithm graphicRef74649" href="/z/d/graphic/74649.html" rel="external">
          algorithm 2
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef131955" href="/z/d/graphic/131955.html" rel="external">
          algorithm 3
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/96933.html" rel="external">
          "Convulsive status epilepticus in adults: Management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6192.html" rel="external">
          "Management of convulsive status epilepticus in children"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A subset of patients with autoimmune encephalitis present with new-onset refractory status epilepticus (NORSE), which may require iatrogenic-induced coma in an intensive care unit setting with
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         ,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         , or
         <a class="drug drug_general" data-topicid="9754" href="/z/d/drug information/9754.html" rel="external">
          pentobarbital
         </a>
         [
         <a href="#rid67">
          67
         </a>
         ]. Such presentations are best described in patients with anti-N-methyl-D-aspartate (NMDA), anti-gamma-aminobutyric acid A (GABA-A), and anti-gamma-aminobutyric acid B (GABA-B) receptor antibodies [
         <a href="#rid68">
          68-71
         </a>
         ]. In super-refractory status epilepticus, effective seizure control may not be realized until adequate immunosuppression is achieved. (See
         <a class="medical medical_review" href="/z/d/html/132561.html" rel="external">
          "Refractory status epilepticus in adults", section on 'Immunomodulatory therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other aspects of seizure management are reviewed below. (See
         <a class="local">
          'Seizures'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Respiratory failure
         </strong>
         – Respiratory dysfunction in patients with autoimmune encephalitis may be caused by brainstem involvement, associated neuromuscular symptoms, or iatrogenic hypoventilation due to medications administered for seizures. Central hypoventilation requiring artificial ventilation is mostly seen in anti-NMDA receptor encephalitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dysautonomia
         </strong>
         – Severe dysautonomia is a well-recognized feature of anti-NMDA receptor encephalitis but is also seen in brainstem encephalitis and progressive encephalomyelitis with rigidity and myoclonus (PERM) mediated by anti-glycine receptor (GlyR) antibodies. Manifestations may include heart rate and blood pressure instability, gastric dysmotility, and urinary retention.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Careful monitoring and management of heart rate fluctuations and blood pressure are essential in patients with severe dysautonomia. Evidence for symptomatic therapies in patients with autoimmune encephalitis is sparse; when sympathetic overactivity is severe, treatment with nonselective beta blockers, alpha-2 agonists, and/or acetylcholinesterase inhibitors may be required. A pacemaker may be temporarily necessary in patients with severe dysrhythmia (or even asystole) until dysautonomia improves [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients with serious symptomatic postural hypotension can be treated with
         <a class="drug drug_general" data-topicid="9651" href="/z/d/drug information/9651.html" rel="external">
          midodrine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">
          fludrocortisone
         </a>
         , or
         <a class="drug drug_general" data-topicid="93840" href="/z/d/drug information/93840.html" rel="external">
          droxidopa
         </a>
         , in addition to sufficient hydration and compressive stockings. (See
         <a class="medical medical_review" href="/z/d/html/5105.html" rel="external">
          "Treatment of orthostatic and postprandial hypotension", section on 'Pharmacotherapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Rare patients with severe gastrointestinal dysmotility refractory to standard symptomatic therapies may require temporary total
         <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">
          parenteral nutrition
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/2532.html" rel="external">
          "Treatment of gastroparesis", section on 'Refractory symptoms'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Those with urinary retention often require an indwelling catheter during the acute phase of illness. Generally, supportive measures are able to be weaned once the patient is recovering.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fevers
         </strong>
         – High fevers can be a manifestation of autoimmune encephalitis due to hypothalamic involvement or severe dysautonomia. Incidence and risk factors are not well studied, however, and central fever should be considered a diagnosis of exclusion after careful investigation of infectious sources.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hyponatremia
         </strong>
         – Hyponatremia is common in patients who are acutely ill with autoimmune encephalitis, especially those with antibodies against leucine-rich glioma inactivated 1 (LGI1) protein. In most cases, this is due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH), and fluid restriction is often sufficient. In rare cases, controlled slow correction of sodium levels is required to prevent central pontine myelinolysis. (See
         <a class="medical medical_review" href="/z/d/html/2357.html" rel="external">
          "Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4182529438">
         <span class="h2">
          Psychosis and mood disturbances
         </span>
         <span class="headingEndMark">
          —
         </span>
         Agitation and psychosis are prominent symptoms in many patients [
         <a href="#rid73">
          73
         </a>
         ]. To ensure safety and prevention of self-harm, nonpharmacologic measures including padding and soft restraints should be utilized when appropriate.
        </p>
        <p>
         Despite these measures, antipsychotic medications and benzodiazepines are commonly required, sometimes at high doses to adequately ensure sedation. Specific considerations in patients with autoimmune encephalitis include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with anti-NMDA receptor encephalitis are particularly sensitive to extrapyramidal side effects of antipsychotic agents [
         <a href="#rid74">
          74
         </a>
         ]. Patients may experience worsening of catatonia or involuntary movements. Cases of neuroleptic malignant syndrome have been described in these patients, although symptoms may overlap with the disease itself and establishing causality can be difficult [
         <a href="#rid75">
          75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinicians should maintain a high index of suspicion for toxicities when using antipsychotic agents. Offending drugs should be stopped and substituted with an alternative therapy less likely to exacerbate movements, such as benzodiazepines.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Certain agents may have clinically important effects on seizure threshold (eg,
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ). Some experts advocate avoiding these medications in patients with autoimmune encephalitis who have clinical or subclinical seizures or lateralized periodic discharges on EEG [
         <a href="#rid76">
          76,77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Agents with risk of QT interval prolongation (eg,
         <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">
          ziprasidone
         </a>
         , intravenous
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ) should be used very carefully or avoided in patients with dysautonomic symptoms such as severe bradycardia or heart block [
         <a href="#rid78">
          78
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Manic symptoms may be a presenting symptom in some patients and are well described in anti-NMDA receptor encephalitis [
         <a href="#rid79">
          79
         </a>
         ]. Mood stabilizers such as
         <a class="drug drug_general" data-topicid="10035" href="/z/d/drug information/10035.html" rel="external">
          valproic acid
         </a>
         and
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         are preferred over other agents, especially in patients with comorbid seizures [
         <a href="#rid73">
          73
         </a>
         ]. Elimination or dose reductions of relevant medications may also improve behavior in some patients (eg, steroids, benzodiazepines).
        </p>
        <p>
         Psychosis and mood disturbances may improve rapidly with successful immunomodulatory therapy, and the need for medications should be reassessed at regular intervals. Clinicians should strive for monotherapy or at least dose reductions as much as possible. Many patients can be fully tapered off of symptomatic medications after clinical status has improved.
        </p>
        <p class="headingAnchor" id="H1724175022">
         <span class="h2">
          Seizures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunomodulatory therapy has important antiseizure effects in autoimmune encephalitis caused by antibodies against neuronal cell-surface antigens such as NMDA receptor, LGI1, and GABA-B receptor. Such therapy is felt to be far more effective than antiseizure medications, emphasizing the importance of early treatment [
         <a href="#rid1">
          1,28,80-83
         </a>
         ].
        </p>
        <p>
         Early in the course, many patients also require antiseizure medications to treat focal seizures effectively [
         <a href="#rid84">
          84
         </a>
         ]. Severe seizures, including status epilepticus, warrant acute treatment with benzodiazepines and intravenous antiseizure medications. (See
         <a class="local">
          'Intensive care management'
         </a>
         above.).
        </p>
        <p>
         Based on observational data, sodium channel blockers (eg,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10268" href="/z/d/drug information/10268.html" rel="external">
          lacosamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9545" href="/z/d/drug information/9545.html" rel="external">
          lamotrigine
         </a>
         ) may be preferred over other agents for patients with anti-LGI1 encephalitis and possibly other antibody-mediated syndromes [
         <a href="#rid80">
          80,81
         </a>
         ].
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          Levetiracetam
         </a>
         should be used with caution based on several reports of serious behavioral dysfunction (including suicidality) after initiation of levetiracetam in patients with anti-LGI1 encephalitis not yet controlled with immunomodulatory therapy [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
         The natural history of seizures in patients with autoimmune encephalitis appears to be favorable, although risk may vary depending on etiology and the presence of permanent structural deficits. In a nationwide cohort study that included 153 patients with anti-NMDA receptor, anti-LGI1, or anti-GABA-B receptor encephalitis, 72 percent of patients had one or more seizures and 89 percent reached seizure freedom over a median follow-up of 27 months [
         <a href="#rid81">
          81
         </a>
         ]. Median time to seizure freedom was approximately two months. Almost all surviving patients, including those presenting with status epilepticus, were able to be weaned off antiseizure medications after immunomodulatory therapy and resolution of encephalitis. Other data suggest that risk of chronic epilepsy may be increased in patients presenting with NORSE [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
         Decisions about tapering medications should be individualized. Factors to consider in assessing risk of recurrent seizures include the type of antibody, the level of recovery, MRI and EEG findings, and tolerability of the antiseizure medication regimen. It is often reasonable to consider reducing to monotherapy or tapering off antiseizure medication after one year, at least in patients with antibodies against neuronal cell-surface antigens who have been seizure-free since the acute phase of illness.
        </p>
        <p class="headingAnchor" id="H414063039">
         <span class="h2">
          Movement disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mild movement disorders do not require symptomatic therapy and usually improve with immunomodulatory therapy alone. Severe, dangerous, or disabling movement disorders require directed treatment [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p>
         Patients with dystonia are typically treated with anticholinergics (eg,
         <a class="drug drug_general" data-topicid="10022" href="/z/d/drug information/10022.html" rel="external">
          trihexyphenidyl
         </a>
         ) or muscle relaxants (eg,
         <a class="drug drug_general" data-topicid="9062" href="/z/d/drug information/9062.html" rel="external">
          baclofen
         </a>
         ). Benzodiazepines are more commonly used for myoclonus, PERM, and stiff-person syndrome [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4887.html" rel="external">
          "Treatment of dystonia in children and adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4888.html" rel="external">
          "Treatment of myoclonus"
         </a>
         .)
        </p>
        <p>
         Catatonia is typically treated with intravenous
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         [
         <a href="#rid73">
          73,86
         </a>
         ]. For severe cases of catatonia, there are reports of electroconvulsive therapy being used effectively, although the risks for long-term cognitive adverse effects should be considered. (See
         <a class="medical medical_review" href="/z/d/html/15869.html" rel="external">
          "Catatonia: Treatment and prognosis"
         </a>
         .)
        </p>
        <p>
         Severe chorea, athetosis, and ballism can be treated with antipsychotic agents (eg,
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         ) or dopamine depleting agents (eg,
         <a class="drug drug_general" data-topicid="9476" href="/z/d/drug information/9476.html" rel="external">
          tetrabenazine
         </a>
         ). Patients require careful monitoring to avoid paradoxical worsening of other involuntary movements. (See
         <a class="medical medical_review" href="/z/d/html/14133.html" rel="external">
          "Overview of chorea", section on 'Management of chorea'
         </a>
         .)
        </p>
        <p>
         A trial of
         <a class="drug drug_general" data-topicid="8994" href="/z/d/drug information/8994.html" rel="external">
          carbidopa-levodopa
         </a>
         or a dopamine agonist is reasonable in patients with acquired parkinsonism or severe akinetic-rigid syndrome [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3232570352">
         <span class="h2">
          Sleep disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sleep disorders are common and underrecognized in patients with autoimmune encephalitis [
         <a href="#rid87">
          87
         </a>
         ]. Improving sleep quality may facilitate control of neuropsychiatric symptoms including agitation, psychosis, and seizures. Efforts should focus on achieving and maintaining a healthy sleep cycle through behavioral modifications (environmental conditioning and sleep hygiene), appropriate medication scheduling (eg, dosing glucocorticoids in the morning instead of twice per day or evening), and appropriate use of pharmacotherapy for insomnia [
         <a href="#rid74">
          74,87
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/97849.html" rel="external">
          "Poor sleep and insomnia in hospitalized adults", section on 'Pharmacotherapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2029904378">
         <span class="h1">
          PROGNOSIS AND RECOVERY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune encephalitis is a heterogeneous disorder, and prognosis varies across different subtypes and etiologies. In general, antibody-mediated disorders with antibodies against neuronal cell-surface antigens tend to be the most responsive to immunomodulatory therapy, but residual neurocognitive dysfunction may last for months to years. Patients with paraneoplastic encephalitis associated with classic onconeuronal antibodies more often have a progressive course and competing risks due to their underlying malignancy.
        </p>
        <p>
         The natural history of specific disorders is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/15759.html" rel="external">
          "Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2649154100">
         <span class="h2">
          Multidisciplinary care needs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients recovering from autoimmune encephalitis require multidisciplinary care, the extent of which depends on the severity of the initial disease, response to treatment, and the number and magnitude of residual deficits [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
         Many patients require longitudinal psychiatric care as well as subspecialty neurology care for management of epilepsy, movement disorders, ataxia, and sleep disorders. Patients with paraneoplastic autoimmune encephalitis require close collaboration between neurology and oncology for optimal treatment and monitoring. Occasionally, patients with gastrointestinal dysmotility may require care with gastroenterology and autonomic specialists.
        </p>
        <p>
         Patients who require maintenance immunomodulatory therapy and those with coexisting autoimmune disorders may benefit from comanagement with rheumatology to streamline immunomodulatory therapy and laboratory monitoring [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H479115033">
         <span class="h2">
          Neurocognitive rehabilitation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cognitive impairment is the most common residual symptom after autoimmune encephalitis [
         <a href="#rid89">
          89
         </a>
         ]. Patients may have deficits in episodic verbal memory, attention and executive function, and visuospatial function. In cohort studies of patients with anti-N-methyl-D-aspartate (NMDA) receptor, anti-leucine-rich glioma inactivated 1 (LGI1), and mixed-subtype encephalitis, nearly all patients have cognitive deficits across multiple domains at early timepoints in the postacute setting [
         <a href="#rid61">
          61,89-92
         </a>
         ]. Cognitive recovery occurs in most patients by two to four years, often most rapidly in the first six months, with residual cognitive deficits present in approximately one-third of patients [
         <a href="#rid89">
          89,91
         </a>
         ].
        </p>
        <p>
         Residual psychiatric symptoms are also highly prevalent but improve over time. A residual mood disorder was present in 30 percent of survivors of mixed-subtype encephalitis at a mean of 18 months' follow-up [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
         We encourage patients to engage in occupational, speech, and cognitive therapy during recovery. Formal neuropsychologic testing can be obtained to guide treatment and serve as a basis for comparison at follow-up time points. Although interventions have not been systematically evaluated, several case reports suggest positive outcomes after neuropsychologic rehabilitation [
         <a href="#rid93">
          93-95
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H61989814">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Avoid treatment delay
         </strong>
         – In patients meeting criteria for definite autoimmune limbic encephalitis  (
         <a class="graphic graphic_table graphicRef111085" href="/z/d/graphic/111085.html" rel="external">
          table 5
         </a>
         ), probable anti-N-methyl-D-aspartate (NMDA) receptor encephalitis  (
         <a class="graphic graphic_table graphicRef111082" href="/z/d/graphic/111082.html" rel="external">
          table 2
         </a>
         ), or probable anti-leucine-rich glioma inactivated 1 (LGI1) encephalitis, immunomodulatory therapy should be started as soon as infectious encephalitis is ruled out by cerebrospinal fluid (CSF) results. Delayed treatment is associated with poor outcomes. (See
         <a class="local">
          'Timing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treat triggers
         </strong>
         – All potential triggers of autoimmunity should be promptly addressed, including treatment of the tumor in paraneoplastic cases, treatment of active infections, and removal of iatrogenic triggers such as immune checkpoint inhibitor (ICI) therapy. (See
         <a class="local">
          'Triggers (tumor, infection, drugs)'
         </a>
         above and
         <a class="local">
          'Antitumor therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial immunomodulatory therapy –
         </strong>
         There is broad agreement that high-dose glucocorticoids, intravenous immunoglobulin (
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         ), and therapeutic plasma exchange (TPE) are reasonable first-line therapies, but high-quality evidence on superiority of one agent or combination of agents over another is lacking. We base initial decisions primarily on suspected pathogenic mechanism  (
         <a class="graphic graphic_table graphicRef135170" href="/z/d/graphic/135170.html" rel="external">
          table 1
         </a>
         ) and disease severity  (
         <a class="graphic graphic_algorithm graphicRef142786" href="/z/d/graphic/142786.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Pathogenic mechanism'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antibody-mediated or unknown mechanism
         </strong>
         – For such patients with severe disease (eg, respiratory failure, severe dysautonomia, refractory status epilepticus) and those with probable or definite anti-NMDA receptor encephalitis, we suggest high-dose glucocorticoids plus either
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         or TPE rather than glucocorticoids alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In most other patients, we start with high-dose glucocorticoids and then add IVIG or TPE if there is no improvement by 14 days from the start of the steroid course. (See
         <a class="local">
          'Antibody-mediated mechanism'
         </a>
         above and
         <a class="local">
          'Administration of specific therapies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients who do not respond adequately to two first-line therapies, we suggest adding
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). If there is no improvement following rituximab (eg, four weeks after first dose), we begin
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         . In severe cases, cyclophosphamide may be started at the same time as rituximab. (See
         <a class="local">
          'Rituximab'
         </a>
         above and
         <a class="local">
          'Cyclophosphamide'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          T cell-mediated mechanism
         </strong>
         – For patients with a classic onconeuronal antibody or high-risk cancer with a consistent neurologic phenotype, we suggest initial treatment with high-dose glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients who do not respond adequately to steroids and have a confirmed onconeuronal antibody, we suggest
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         rather than
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         or other therapies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         or TPE is a reasonable second-line therapy before starting cyclophosphamide in patients with severe disease and pending antibodies. (See
         <a class="local">
          'T cell-mediated mechanism'
         </a>
         above and
         <a class="local">
          'Glucocorticoids'
         </a>
         above and
         <a class="local">
          'Cyclophosphamide'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment duration and taper
         </strong>
         – Once patients have achieved a maximal clinical response, a tapering strategy is advised to avoid early recurrence. We choose between an oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         taper, monthly intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         (IVMP), and monthly
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         for an average of two to six months.
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          Rituximab
         </a>
         is another option. (See
         <a class="local">
          'Subsequent immunomodulatory therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Relapsed disease
         </strong>
         – Approximately 10 to 50 percent of patients with antibody-mediated disorders experience relapse during or after taper of immunomodulatory therapy. Most such patients require a more extended period of immunomodulatory therapy, depending on the drug administered. (See
         <a class="local">
          'Relapsed disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prognosis and recovery
         </strong>
         – Autoimmune encephalitis is a heterogeneous disorder, and prognosis varies across different subtypes and etiologies. Many patients have prolonged cognitive and psychiatric morbidity and require multidisciplinary care and rehabilitation. (See
         <a class="local">
          'Prognosis and recovery'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007; 61:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keime-Guibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graus F, Keime-Guibert F, Reñe R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124:1138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bataller L, Graus F, Saiz A, et al. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rojas I, Graus F, Keime-Guibert F, et al. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology 2000; 55:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloch MH, Hwang WC, Baehring JM, Chambers SK. Paraneoplastic limbic encephalitis: ovarian cancer presenting as an amnesic syndrome. Obstet Gynecol 2004; 104:1174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008; 7:327.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graus F, Vogrig A, Muñiz-Castrillo S, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm 2021; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol 2011; 18:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathew RM, Vandenberghe R, Garcia-Merino A, et al. Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology 2007; 68:900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013; 12:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson D, Nathoo N, Henry M, et al. Oophorectomy in NMDA receptor encephalitis and negative pelvic imaging. Pract Neurol 2020.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balu R, McCracken L, Lancaster E, et al. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology 2019; 92:e244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nosadini M, Eyre M, Molteni E, et al. Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis. JAMA Neurol 2021; 78:1333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry 2021; 92:757.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson JA, Schneider BJ, Brahmer J, et al. Management of Immunotherapy-Related Toxicities, Version 1.2019. J Natl Compr Canc Netw 2019; 17:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams TJ, Benavides DR, Patrice KA, et al. Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer. JAMA Neurol 2016; 73:928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28:iv119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018; 36:1714.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edridge A, Namazzi R, Tebulo A, et al. Viral, Bacterial, Metabolic, and Autoimmune Causes of Severe Acute Encephalopathy in Sub-Saharan Africa: A Multicenter Cohort Study. J Pediatr 2023; 258:113360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodriguez A, Klein CJ, Sechi E, et al. LGI1 antibody encephalitis: acute treatment comparisons and outcome. J Neurol Neurosurg Psychiatry 2022; 93:309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fang B, McKeon A, Hinson SR, et al. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis. JAMA Neurol 2016; 73:1297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobin WO, Guo Y, Krecke KN, et al. Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 2017; 140:2415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz-Lopetegi A, de Bruijn MAAM, Boukhrissi S, et al. Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment. Neurol Neuroimmunol Neuroinflamm 2020; 7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dubey D, Britton J, McKeon A, et al. Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy. Ann Neurol 2020; 87:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeSena AD, Noland DK, Matevosyan K, et al. Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-N-methyl-D-aspartate receptor antibody encephalitis: A retrospective review. J Clin Apher 2015; 30:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang Y, Huang HJ, Chen WB, et al. Clinical efficacy of plasma exchange in patients with autoimmune encephalitis. Ann Clin Transl Neurol 2021; 8:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher 2019; 34:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nosadini M, Thomas T, Eyre M, et al. International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurol Neuroimmunol Neuroinflamm 2021; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thaler FS, Zimmermann L, Kammermeier S, et al. Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry. Neurol Neuroimmunol Neuroinflamm 2021; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papachristos DA, Oon S, Hanly JG, Nikpour M. Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review. Semin Arthritis Rheum 2021; 51:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Groot K, Harper L, Jayne DR, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Le Guenno G, Mahr A, Pagnoux C, et al. Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides. Arthritis Rheum 2011; 63:1435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014; 13:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee WJ, Lee ST, Moon J, et al. Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study. Neurotherapeutics 2016; 13:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee WJ, Lee ST, Shin YW, et al. Teratoma Removal, Steroid, IVIG, Rituximab and Tocilizumab (T-SIRT) in Anti-NMDAR Encephalitis. Neurotherapeutics 2021; 18:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med 2019; 381:2114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020; 19:402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen D, Gallagher S, Monson NL, et al. Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies. J Clin Med 2016; 5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019; 394:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blackburn KM, Denney DA, Hopkins SC, Vernino SA. Low Recruitment in a Double-Blind, Placebo-Controlled Trial of Ocrelizumab for Autoimmune Encephalitis: A Case Series and Review of Lessons Learned. Neurol Ther 2022; 11:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheibe F, Prüss H, Mengel AM, et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology 2017; 88:366.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dinoto A, Cheli M, Bratina A, et al. Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review. J Neuroimmunol 2021; 356:577586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howard JF Jr, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2021; 20:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lim JA, Lee ST, Moon J, et al. New feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2. J Neuroimmunol 2016; 299:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang Y, Lee WJ, Lee HS, et al. Tofacitinib treatment for refractory autoimmune encephalitis. Epilepsia 2021; 62:e53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang Y, Woo KA, Lee ST, et al. Cerebral autoinflammatory disease treated with anakinra. Ann Clin Transl Neurol 2018; 5:1428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang Y, Lee WJ, Lee HS, et al. Anakinra treatment for refractory cerebral autoinflammatory responses. Ann Clin Transl Neurol 2022; 9:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scheibe F, Ostendorf L, Reincke SM, et al. Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis. J Neurol 2020; 267:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratuszny D, Skripuletz T, Wegner F, et al. Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis. Front Neurol 2020; 11:602102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-Chiriboga AS, Flanagan EP. Diagnostic and Therapeutic Approach to Autoimmune Neurologic Disorders. Semin Neurol 2018; 38:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly H, Johnson J, Jakubecz C, et al. Prevalence of iatrogenic CNS inflammation at a tertiary neuroimmunology clinic. J Neuroimmunol 2022; 370:577928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalmau J, Graus F. Antibody-Mediated Encephalitis. N Engl J Med 2018; 378:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Sonderen A, Petit-Pedrol M, Dalmau J, Titulaer MJ. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis. Nat Rev Neurol 2017; 13:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shin YW, Lee ST, Park KI, et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord 2018; 11:1756285617722347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang JH, Liu EN, Nguyen L, et al. Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis. Neurology 2023; 101:e2300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Sonderen A, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology 2016; 87:1449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ariño H, Armangué T, Petit-Pedrol M, et al. Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome. Neurology 2016; 87:759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Sonderen A, Ariño H, Petit-Pedrol M, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology 2016; 87:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abboud H, Probasco J, Irani SR, et al. Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. J Neurol Neurosurg Psychiatry 2021; 92:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nosadini M, Mohammad SS, Ramanathan S, et al. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother 2015; 15:1391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harutyunyan G, Hauer L, Dünser MW, et al. Risk Factors for Intensive Care Unit Admission in Patients with Autoimmune Encephalitis. Front Immunol 2017; 8:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsch LJ, Gaspard N, van Baalen A, et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 2018; 59:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan PW, Probasco J. Limbic and new onset refractory tonic status epilepticus (NORSE) in anti-NMDAR encephalitis. Clin Neurophysiol Pract 2017; 2:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panda PK, Sharawat IK, Mehta S, et al. Anti-N-methyl-d-aspartate Receptor Encephalitis Presenting as New-onset Refractory Status Epilepticus Responding to Rituximab in an Adolescent Girl. J Pediatr Neurosci 2021; 16:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Coevorden-Hameete MH, de Bruijn MAAM, de Graaff E, et al. The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies. Brain 2019; 142:1631.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nazif TM, Vázquez J, Honig LS, Dizon JM. Anti-N-methyl-D-aspartate receptor encephalitis: an emerging cause of centrally mediated sinus node dysfunction. Europace 2012; 14:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bost C, Pascual O, Honnorat J. Autoimmune encephalitis in psychiatric institutions: current perspectives. Neuropsychiatr Dis Treat 2016; 12:2775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohammad SS, Jones H, Hong M, et al. Symptomatic treatment of children with anti-NMDAR encephalitis. Dev Med Child Neurol 2016; 58:376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarmiento RJC, Diestro JDB, Antonio AKD, et al. Neuroleptic Malignant Syndrome in a Patient With Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Case Report and Review of Related Literature. Neurohospitalist 2022; 12:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuld A, Kühn M, Haack M, et al. A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia. Pharmacopsychiatry 2000; 33:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anzellotti F, Capasso M, Frazzini V, Onofrj M. Olanzapine-related repetitive focal seizures with lingual dystonia. Epileptic Disord 2016; 18:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mackin P. Cardiac side effects of psychiatric drugs. Hum Psychopharmacol 2008; 23 Suppl 1:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Diwani A, Handel A, Townsend L, et al. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry 2019; 6:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feyissa AM, López Chiriboga AS, Britton JW. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm 2017; 4:e353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology 2019; 92:e2185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Binks SNM, Klein CJ, Waters P, et al. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes. J Neurol Neurosurg Psychiatry 2018; 89:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson J, Bi M, Murchison AG, et al. The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 2018; 141:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dalmau J, Rosenfeld MR. Autoimmune encephalitis update. Neuro Oncol 2014; 16:771.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaspard N, Foreman BP, Alvarez V, et al. New-onset refractory status epilepticus: Etiology, clinical features, and outcome. Neurology 2015; 85:1604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baizabal-Carvallo JF, Jankovic J. Autoimmune and paraneoplastic movement disorders: An update. J Neurol Sci 2018; 385:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muñoz-Lopetegi A, Graus F, Dalmau J, Santamaria J. Sleep disorders in autoimmune encephalitis. Lancet Neurol 2020; 19:1010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbatemarco JR, Rodenbeck SJ, Day GS, et al. Autoimmune Neurology: The Need for Comprehensive Care. Neurol Neuroimmunol Neuroinflamm 2021; 8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abboud H, Briggs F, Buerki R, et al. Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adults. J Neurol Sci 2022; 434:120124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guasp M, Rosa-Justicia M, Muñoz-Lopetegi A, et al. Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders. Lancet Neurol 2022; 21:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heine J, Kopp UA, Klag J, et al. Long-Term Cognitive Outcome in Anti-N-Methyl-D-Aspartate Receptor Encephalitis. Ann Neurol 2021; 90:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finke C, Prüss H, Heine J, et al. Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies. JAMA Neurol 2017; 74:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perna R, Harik L, Arenivas A. Three case studies of nonparaneoplastic limbic encephalitis (NPLE) in young adult males: Onset, course, and recovery following rehabilitation services. Appl Neuropsychol Child 2019; 8:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corallo F, Lo Buono V, Di Cara M, et al. The role of cognitive rehabilitation in limbic encephalitis: A case report. Medicine (Baltimore) 2018; 97:e13223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bach LJ. Long term rehabilitation management and outcome of anti-NMDA receptor encephalitis: case reports. NeuroRehabilitation 2014; 35:863.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 140809 Version 3.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21416487" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17262855" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10727484" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11353730" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11157570" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10980743" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12764061" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15516442" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Paraneoplastic limbic encephalitis: ovarian cancer presenting as an amnesic syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18339348" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Paraneoplastic syndromes of the CNS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34006622" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20880069" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Screening for tumours in paraneoplastic syndromes: report of an EFNS task force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17151337" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23290630" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33033162" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Oophorectomy in NMDA receptor encephalitis and negative pelvic imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30578370" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34542573" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis: A Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26906964" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A clinical approach to diagnosis of autoimmune encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33649022" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30865922" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Management of Immunotherapy-Related Toxicities, Version 1.2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27271951" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28881921" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29442540" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36828342" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Viral, Bacterial, Metabolic, and Autoimmune Causes of Severe Acute Encephalopathy in Sub-Saharan Africa: A Multicenter Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34824144" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : LGI1 antibody encephalitis: acute treatment comparisons and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27618707" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Novel Meningoencephalomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29050399" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32123047" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Neurologic syndromes related to anti-GAD65: Clinical and serologic response to treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31782181" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Randomized Placebo-Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25664728" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-N-methyl-D-aspartate receptor antibody encephalitis: A retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33609012" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical efficacy of plasma exchange in patients with autoimmune encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31180581" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34301820" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34599001" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis: Real-world Evidence From the GENERATE Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33360230" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19451574" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21337321" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24360484" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27215218" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32880854" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Teratoma Removal, Steroid, IVIG, Rituximab and Tocilizumab (T-SIRT) in Anti-NMDAR Encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31774956" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32333898" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27886126" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31495497" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35129803" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Low Recruitment in a Double-Blind, Placebo-Controlled Trial of Ocrelizumab for Autoimmune Encephalitis: A Case Series and Review of Lessons Learned.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10363983" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Proteasome inhibitors: a novel class of potent and effective antitumor agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28003505" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33975246" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34146511" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27725107" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : New feasible treatment for refractory autoimmune encephalitis: Low-dose interleukin-2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33656171" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Tofacitinib treatment for refractory autoimmune encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30480037" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Cerebral autoinflammatory disease treated with anakinra.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35040583" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Anakinra treatment for refractory cerebral autoinflammatory responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31630242" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33414761" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30011418" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Diagnostic and Therapeutic Approach to Autoimmune Neurologic Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35853358" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Prevalence of iatrogenic CNS inflammation at a tertiary neuroimmunology clinic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29490181" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Antibody-Mediated Encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28418022" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29399043" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Treatment strategies for autoimmune encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37827848" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Survival Analysis of Immunotherapy Effects on Relapse Rate in Pediatric and Adult Autoimmune Encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27590293" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27466467" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27371488" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : The clinical spectrum of Caspr2 antibody-associated disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33649021" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26559389" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Immune therapy in autoimmune encephalitis: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28804482" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Risk Factors for Intensive Care Unit Admission in Patients with Autoimmune Encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29399791" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30214986" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Limbic and new onset refractory tonic status epilepticus (NORSE) in anti-NMDAR encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36531781" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Anti-N-methyl-d-aspartate Receptor Encephalitis Presenting as New-onset Refractory Status Epilepticus Responding to Rituximab in an Adolescent Girl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24462240" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31009048" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22345374" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Anti-N-methyl-D-aspartate receptor encephalitis: an emerging cause of centrally mediated sinus node dysfunction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27822050" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Autoimmune encephalitis in psychiatric institutions: current perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26330176" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Symptomatic treatment of children with anti-NMDAR encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34950391" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Neuroleptic Malignant Syndrome in a Patient With Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Case Report and Review of Related Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10855462" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26898965" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Olanzapine-related repetitive focal seizures with lingual dystonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18098218" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Cardiac side effects of psychiatric drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30765329" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28680914" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Antiepileptic drug therapy in patients with autoimmune epilepsy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30979857" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29055902" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29272336" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The importance of early immunotherapy in patients with faciobrachial dystonic seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24637228" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Autoimmune encephalitis update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26296517" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : New-onset refractory status epilepticus: Etiology, clinical features, and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29406902" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Autoimmune and paraneoplastic movement disorders: An update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33212053" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Sleep disorders in autoimmune encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34131068" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Autoimmune Neurology: The Need for Comprehensive Care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34998237" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36115362" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34595771" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Long-Term Cognitive Outcome in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27893017" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29185868" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Three case studies of nonparaneoplastic limbic encephalitis (NPLE) in young adult males: Onset, course, and recovery following rehabilitation services.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30508904" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The role of cognitive rehabilitation in limbic encephalitis: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25323083" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Long term rehabilitation management and outcome of anti-NMDA receptor encephalitis: case reports.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
